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Abstract
Objective—Inconclusive findings about infection risks, importantly the use of 
immunosuppressive medications, in patients who have undergone large-joint total joint 
arthroplasty challenge efforts to provide evidenced-based perioperative total joint arthroplasty 
recommendations to improve surgical outcomes. Thus, the aim of this study was to describe risk 
factors for developing a postoperative infection in patients undergoing TJA of a large joint [total 
hip arthroplasty, total knee arthroplasty, or total shoulder arthroplasty] by identifying clinical and 
demographic factors, including the use of high risk medications (i.e., prednisone and 
immunosuppressive medications) and diagnoses (i.e., rheumatoid arthritis [RA], osteoarthritis 
[OA], gout, obesity, diabetes mellitus), that are linked to infection status, controlling for length of 
follow-up.
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Methods—A retrospective, case-control study (N = 2,212) using de-identified patient health 
claims information from a commercially-insured, U.S. dataset representing 15 million patients 
annually (January 1, 2007 - December 31, 2009) was conducted. Descriptive statistics, t-test, chi-
square test, Fisher's exact test, and multivariate logistic regression were used.
Results—Male gender (OR = 1.42; p < .001), diagnosis of RA (OR = 1.47; p = .031), diabetes 
mellitus (OR = 1.38, p = .001), obesity (OR = 1.66, p < .001) or gout (OR = 1.95; p = .001), and a 
prescription for prednisone (OR = 1.59; p < .001) predicted a post-operative infection following 
total joint arthroplasty. Persons with post-operative joint infections were significantly more likely 
to be prescribed allopurinol (p = .002) and colchicine (p = .006; no significant difference was 
found for the use of specific disease modifying anti-rheumatic drugs and TNF-α inhibitors.
Conclusion—High-risk, post-operative joint infection groups were identified allowing for 
precautionary clinical measures to be taken.
Keywords
Total joint arthroplasty; infections; risk factors; immunosuppressive medications; perioperative 
management; case-control study
1. Introduction
Due to the high number of persons undergoing total large joint arthroplasty in the U.S., a 
clear understanding of the risk of infection and related hospital readmissions and surgical 
revisions is important [1-8]. Specifically, in the U.S., there were 719,000 total knee 
arthroplasties -, 332,000 total hip arthroplasties, and 29,127 total shoulder arthroplasties 
carried out in 2010 with annual costs estimated to be$18.7 billion.[1-3] Infection is reported 
as a leading cause of hospital readmission following a total joint arthroplasty (post-operative 
joint infection rates: 0.3% - 0.7%).[4-6] An estimated 14% of hospital readmissions 
following total joint arthroplasty are a result of deep or superficial surgical site infection and 
44% of joint revisions are a result of infections.[4-8]
In efforts to improve infection rates, prior research studies have identified high-risk groups 
which have included: male gender (odds ratio [OR]: total knee arthroplasty - 1.89; total 
shoulder arthroplasty - 2.59; total joint arthroplasty - 1.79); age older or younger than 56 - 
65 years (OR: total knee arthroplasty - 1.42 - 2.59); diagnosis of diabetes mellitus (DM; OR: 
total knee arthroplasty - 1.28; total hip arthroplasty - 1.77); scoring at or higher than 2 on the 
American Society of Anesthesiologist Scale (OR: total knee arthroplasty - 1.42 - 1.65; total 
hip arthroplasty - 1.95 - 2.74; TSA - 1.41); history of cancer (OR: total knee arthroplasty - 
11.73); higher Charlson Comorbidity Score (OR: total joint arthroplasty - 2.29 [Score ≥ 2]; 
total knee arthroplasty - 2 [Score > 3]); current smoker (OR: total knee arthroplasty or total 
hip arthroplasty - 1.41); and Body Mass Index ≥ 35 (OR: total knee arthroplasty - 1.47; total 
hip arthroplasty -3.02; total shoulder arthroplasty - 2.48). Yet, there are inconsistencies in the 
variables investigated and study findings.[7-18] Similarly, many of these risk factors are 
largely unmodifiable in the perioperative period.
Because of the potential for modification, an understanding of risks of immunosuppressive 
medications on rates of infection and readmission following total joint arthroplasty is 
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needed. Prior research on this topic is largely based on studies of rheumatoid arthritis (RA) 
patients.[8,19,20] Research suggests use of traditional disease modifying antirheumatic 
drugs (DMARDs), a nonbiologic class of immunosuppressive medications used to treat RA, 
prior to surgery does not increase infection risk.[20] In contrast, steroid use has been found 
to increase risks of infection and hospital readmission.[19,21] There are conflicting findings 
on TNF inhibitor use (biologic medications used to treat RA) and infection risk.[20-26]
Studies investigating the role of immunosuppressive medications in RA patients have not 
clearly described the role of treatment versus disease-related (inflammatory arthritis versus 
noninflammatory arthritis) effects on postoperative infection risks. [9,10,27-29] Two 
retrospective U.S. studies found no difference in infection rates between those diagnosed 
with RA versus osteoarthritis (OA) in persons who had undergone a total hip arthroplasty or 
total knee arthroplasty.[9,10] Yet, a number of studies have reported increased risks of 
infection in patients with RA ranging from two to four times that of patients with OA.
[5,15,19,27] Singh and colleagues (N = 34,311) recently reported that persons with RA are 
1.29 times more likely to be readmitted to the hospital for post-surgical complications 
(infection leading cause), and that these rates were increasing yearly (0.85, 1.37, and 1.63 in 
2009, 2010, and 2011, respectively).[4] Interpretation of the literature is complicated by the 
inconsistent antibiotic protocols, definitions of infection, and sampling.[28]
Evidence-based perioperative management for total joint arthroplasty is limited by the lack 
of conclusive research findings about risk factors, the role of immunosuppressive 
medications, and the role of type of arthritis (OA versus RA) in the development of an 
infection following total joint arthroplasty.[9,10,27, 29] The aim of this study was to 
describe risk factors for developing post-operative infections in patients undergoing total 
joint arthroplasty of a large joint (total hip arthroplasty, total knee arthroplasty, or total 
shoulder arthroplasty). To achieve this aim, initially we identified clinical and demographic 
factors, including the use of high risk medications (i.e., prednisone and immunosuppressive 
medications) and diagnoses (i.e., gout, obesity, DM, RA, OA), that are linked to infection 
status, controlling for length of follow-up by comparing cases and control and using logistic 
regression modeling. During this iterative process, we further explored the potential for 
clinical and demographic factors that moderate the relationship between RA/OA diagnosis 
and infections post-operatively.
2. Materials and Methods
2.1. Procedure and Sample
De-identified patient health claims information was extracted retrospectively from a dataset 
representing a commercially-insured, U.S. population of 15 million patients annually from 
January 1, 2007 to December 31, 2009. This dataset includes 1,284,681 prescribers and 
3,631 health care provider designations from all geographic regions in the U.S. Patient-level 
data was extracted including: administrative demographic data (e.g., gender, age), pharmacy 
claims data (e.g., national drug code), and physician and facility claims (e.g., procedure 
codes, diagnosis codes). Medical Institutional Review Board approval was obtained for the 
use of this dataset.
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First, all patients with the diagnosis of OA (ICD-9: 715.0 - 715.9) and RA (ICD-9: 714.0, 
714.2, 714.4) who had a total joint arthroplasty (CPT codes: total knee arthroplasty - 27447; 
total hip arthroplasty - 27130; total shoulder arthroplasty - 23472) were extracted from the 
database which resulted in 55,861 unique persons. Patients who developed a post-operative 
joint infection following total joint arthroplasty surgery (ICD-9: 996.66 - Infection and 
inflammatory reaction due to internal joint prosthesis) were identified as cases (Figure 1). Of 
the 55,861 patients followed during this 2-year period, 1,127 developed a post-operative 
infection following total joint arthroplasty surgery and therefore were defined as cases in this 
study. Only one operative event was included for a given patient. If a patient had more than 
one total joint arthroplasty, only the first surgery was retained in this analysis. The only 
exception to this was if a patient had a subsequent total joint arthroplasty surgery that 
resulted in infection; in this case, only the information from the first surgery associated with 
an infection was retained. Controls were randomly selected to frequency match cases based 
on age (within 10-year increments) with a 1:1 sampling ratio; therefore only persons with 
complete data on matching criteria were eligible. Ten cases had missing data on year of birth 
and were excluded from the study; 11 cases were omitted because they did not have 
confirmation of OA or RA diagnosis, since the corresponding ICD-9 code was listed only 
once in their record; therefore the final sample consisted of 2,212 patients: 1,106 cases and 
1,106 controls.
2.2. Measures
2.2.1. Demographic and clinical characteristics—Demographic information 
extracted from the database included age, gender, and race (White, Other race). We also 
retained information on surgery location (i.e., hip, knee, or shoulder) and time between date 
of surgery and end of study (i.e., length of follow-up in days). Based on prior research, 
ICD-9 codes were used to extract clinical information for comorbid conditions including: 
human immunodeficiency virus infection and acquired immune deficiency syndrome [HIV/
AIDS], immunodeficiency conditions, cancer, systemic lupus erythematosus [SLE], diabetes 
mellitus [DM], obesity/morbid obesity, and gout.[30-33]
We also collected information on concomitant prescription drug information. Prednisone 
was abstracted as dose (mg) and supply (days) for each individual; only prescriptions within 
one month before surgery or following, which we defined as the perioperative period, were 
included. Because the majority of the sample (77%) was not prescribed prednisone, a binary 
variable indicating yes or no to prednisone use was created to include in the analysis. 
Medications were classified as immunosuppressive based on an updated Center for Disease 
Control list of Immunosuppressive Medications.[34]
2.2.2. Infection status—Medical outcome data were used to identify patients receiving 
treatment for post-operative joint infections (ICD-9: 996.66 - Infection and inflammatory 
reaction due to internal joint prosthesis). For each patient, a binary variable was created to 
indicate whether or not the patient received care for an infection attributed to the total joint 
arthroplasty. This variable was used to distinguish cases and controls, and was the outcome 
in this study.
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2.3. Data Analysis
Data were summarized using descriptive statistics. Initially, comparisons of study variables 
between cases and controls were accomplished using the two-sample t-test, Mann-Whitney 
U test, chi-square test of association or Fisher's exact test. Then, a series of logistic 
regression models were used. First, a main effects model was fit to identify demographic and 
clinical characteristics predictive of infection status. In addition to typical demographic/
clinical factors, we also included length of follow-up in each model as an adjustment for 
longer median follow-up among cases relative to controls. Through an iterative process, a 
test of moderation between diagnosis of RA or OA and post-operative infection status was 
conducted using a second logistic regression model which included the interactions between 
diagnosis (RA vs. OA) and the potential moderator variables (i.e., each demographic and 
clinical factor). Due to the concern about estimate stability, interaction terms involving 
conditions of very low prevalence (i.e., cancer, immunodeficiency, SLE, each affecting less 
than 5% of sample) were not included. In a subsequent analysis, all nonsignificant 
interactions were removed from the model. For the significant interaction effects retained, 
the association between RA or OA diagnosis and infection risk was evaluated at each level 
of the moderator variable. The Hosmer-Lemeshow goodness-of-fit test evaluated overall 
model fit, and variance inflation factors were used to check for multicollinearity. For these 
data analyses, SAS version 9.3 was used with an alpha level of .05.
3. Results
3.2. Description of Sample
The mean age of the case-control sample was 59.8 years (SD = 10.2 years). The majority of 
the sample was female (51.1%) and White (83.1%; Table 1). The most common total joint 
arthroplasty was total knee arthroplasty (61.5%), followed by total hip arthroplasty (35.7%) 
and total shoulder arthroplasty (2.8%); the median length of follow up among all patients 
was 555 days. The prevalence of comorbid conditions included obesity (30.5%), DM 
(29.4%), gout (6.4%), SLE (2.5%), cancer (2.5%), an immunodeficiency condition (1.0%), 
and/or HIV/AIDS (0.4%). Nearly one-quarter of patients (22.7%) were prescribed 
prednisone in the two-month perioperative period; 13.5% took at least one 
immunosuppressive medication during the perioperative period. In the total sample, among 
those on prednisone, the median average daily dose was 0.16mg (0.07mg – 0.47mg).
3.3. Identification of Clinical and Demographic Risk Factors
When comparing cases to controls, those with an infection were more likely to be male 
(52.1% vs. 45.7%; p = .002; Table 1). Persons who experienced an infection also had a 
longer median length of follow up (577 days) compared with those who did not (526 days; p 
< .001). In addition, persons in the case group (i.e., those with an infection) were more likely 
to have been diagnosed with lupus (3.4% vs. 1.6%; p = .007), DM (34.1% vs. 24.8%; p < .
001), obesity (35.8% vs. 25.2%; p < .001), and gout (8.9% vs. 3.9%; p < .001). Those with 
infections were more likely to have an RA diagnosis compared to those in the control group 
(9.2% vs. 6.1%, p = .005). Consistent with the age-matching of controls with cases, there 
was no difference on age (t = 0.4; p = .7). In addition, cases and controls did not differ on 
race, surgery location, or prevalence of cancer, immunodeficiency conditions, or HIV/AIDS.
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In the bivariate analysis of medication use relative to post-operative infection status, a higher 
proportion of cases were prescribed prednisone (27.7% vs. 17.7%; p < .001) or an 
immunosuppressive medication (16.6% vs. 10.4%; p < .001) at least once during the 
perioperative period, compared with controls. For each immunosuppressive drug used by at 
least five patients in the sample, individual drugs and drug categories were compared 
between cases and controls (Figures 2 and 3). The only significant differences between cases 
and controls for prevalence of specific immunosuppressive drugs and drug categories 
included allopurinol (χ2 = 9.2; p = .002) and colchicine (χ2 = 7.5; p = .006. Figures 2 and 3 
also display, at the top of each bar, the percent of patients using the particular medication (or 
medication class) that were also diagnosed with RA. Given that the sample comprised 8% 
RA patients, medications with RA use prevalence in excess of this demonstrates that more 
RA patients were taking these drugs that would have been expected if both diagnoses were 
equally likely to do so. Nearly all of those using adalimumab, leflunomide, or methotrexate 
were RA patients, while nearly all of those using allopurinol, fluorouracil, or megestrol were 
OA patients (Figure 2). More than two-thirds of those taking a TNFα inhibitor or DMARD 
were diagnosed with RA, regardless of whether they were in the infection (case) group or 
not (Figure 3).
The main effects multiple logistic regression model was significant overall (χ2 = 129.8; p < .
001). Length of follow-up was associated with infection risk. For each additional 100 days 
of follow-up, a patient was 4% more likely to have an infection in a prosthetic joint (OR = 
1.04; p = .004; Table 2). Males, compared to females, were 42% more likely to develop an 
infection post-operatively (OR = 1.42; p < .001). Patients with a DM diagnosis were 38% 
more likely to develop an infection, relative to those without this diagnosis (OR = 1.38; p = .
001). Other comorbid conditions associated with increased infection risk included obesity 
(OR = 1.66, p <.001) and gout (OR = 1.95; p = .001). Controlling for demographic and 
clinical characteristics and length of follow-up, RA patients were 47% more likely to 
develop a post-operative infection, compared to patients with OA (OR = 1.47; p = .031). 
Patients prescribed prednisone within one month before or following total joint arthroplasty 
surgery were 59% more likely to develop an infection, compared to those not prescribed 
prednisone (OR = 1.59; p < .001). Race, total joint arthroplasty location, cancer, SLE, 
presence of an immunodeficiency condition, HIV/AIDS, and use of an immunosuppressive 
medication during the perioperative period were not predictive of post-operative infection in 
the main effects model. The Hosmer-Lemeshow goodness-of-fit test was not significant (χ2 
= 5.2; p = .74), suggesting the model fit the data well. All variance inflation factors were less 
than 1.4, indicating that multicollinearity was not distorting the parameter estimates.
In an effort to investigate treatment versus disease-related effects, the relationship between 
RA/OA diagnosis and infection identified in our primary analysis was explored using a 
second logistic regression model. This moderation model, which contained demographic and 
clinical main effects, days of follow-up, the indicator for RA/OA, and the interaction 
between immunosuppressive medication use and RA/OA diagnosis was significant (χ2 = 
8.3; p = .004). Among those taking immunosuppressive medication(s) (n = 299), there was 
no difference in the odds of infection between RA (n = 71) and OA patients (n = 229; OR = 
0.73, p = .30); however, among those not taking this type of medication (n = 1,913), RA 
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patients (n = 99) were 130% more likely to develop an infection compared with OA patients 
(n = 1,814; OR = 2.30, 95% Confidence Interval: 1.37 – 3.30; p = .001).
4. Discussion
The lack of conclusive research findings about risk factors, importantly the role of 
immunosuppressive medications, in the development of an infection following total joint 
arthroplasty, has limited evidenced-based perioperative management. Similarly there is a 
lack of clarity on the role of disease- versus treatment-related effects on infection risk 
following total joint arthroplasty. In efforts to address these clinical problems, we identified 
risk factors for developing infections following a total joint arthroplasty of a large joint. 
Using an iterative process we also described the moderating relationship between the use 
immunosuppressive medications and the diagnosis of RA/OA in the development of a post-
operative infection.
There is evidence that supports and conflicts with our finding that there is an increased risk 
of infection following total joint arthroplasty in patients with RA versus those with OA. 
Large U.S. and European studies have reported an increased risk of hospital readmissions 
and infections in patients with RA versus those with OA. [4,27,30] In contrast, Namba and 
colleagues did not find an increased risk of infection between persons with RA and OA 
following total hip arthroplasty or total knee arthroplasty in a retrospective analysis of data 
from 2001-2009.[9,10] Considering that the majority and the most recent and large studies 
found an increased risk of postoperative infection in patients with RA, we feel our findings 
are strongly supported; thus, this risk factor should be considered during clinical 
management.
Although the increased infection risk of RA versus OA has been further established, the 
question of disease- versus treatment-related effects remained.[29] Because of the study 
design using a large administrative dataset, we could not directly assess RA disease activity. 
However, importantly in our study, immunosuppressive medication use did not predict 
infection in our main effects model and the use of immunosuppressive medications only 
moderated the relationship between RA/OA diagnosis and infection in the postoperative 
period: while the main effects model demonstrated that RA patients were at an increased risk 
for infection compared with OA patients, the test of moderation indicated this phenomenon 
was only present among those not taking immunosuppressive medications perioperatively. 
These findings support prior studies suggesting there is not an increased infection risk when 
using immunosuppressive medications (DMARDs) prior to surgery.[19, 20] Our study 
conflicts with prior research reporting that patients taking biologic DMARDs within 2 to 4 
weeks of surgery were 5.7 times more likely to develop an infection.[20] Of interest, persons 
in the this same study who had increased RA disease duration were also more likely to 
develop an infection.[20] We found there was not a significant different between cases and 
control on the use of TNF-α inhibitors as a class, and this was bolstered with the case-
control comparison of percentage using adalimumab specifically. We confirmed prior 
evidence to suggest that steroid use increases the risk of infection and hospital readmission.
[8,19]
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Our findings suggesting that, controlling for obesity and DM, gout and medications used to 
treat gout increase infection risk following total joint arthroplasty. These findings are 
supported by one study conducted by Inacio and colleagues (OR - 1.3).[27] Interestingly, a 
recent publication reported 7 cases of crystal induced arthritis followed total joint 
arthroplasty suggesting our understanding of the relationship between gout, total joint 
arthroplasty and infection is evolving and further exploration is needed [35]. Similarly, 
because the increased risk of infection has been described in two diseases with inflammatory 
etiologies (RA and gout), the role of inflammation in the diagnosis of postoperative infection 
also requires further exploration.
Prior research supports study findings that male gender, DM, and obesity predict 
postoperative infection following total joint arthroplasty.[9,10] Interestingly, weight loss has 
also been identified as a risk factor for developing a post-operative infection (OR: 2.3) 
complicating clinical recommendations to obese persons.[27]
The effect of cancer diagnosis on infection risk following total joint arthroplasty is 
conflicting in prior research. [8,31] Findings from this study suggest that persons with a 
history of cancer are not at increased infection risk. Although we did report the use of 
immunosuppressive medication use, which provides insight into cancer as an infection risk 
factor, further prospective research on the effects of cancer stage and specifics of cancer 
treatment should be conducted. Neither our findings nor prior research suggest that those 
diagnosed with HIV/AIDS are at increased risk of infection following total joint 
arthroplasty.[31] Despite our study findings, there are relatively few studies describing the 
risk of HIV/AIDS and cancer and postoperative infection, which limits evidenced-based 
practice.
A study strength is the large number of patients included relative to prior research in this 
area. Because this was a retrospective review of a commercial insurance database, the data 
available was limited by those medications and treatments that were charged by health care 
providers and paid for using insurance coverage. Although this was a large dataset, it 
represents those commercially insured and study findings may not be generalizable to other 
populations, including those without private insurance. The racial/ethnic composition of the 
sample is notrepresentative of the U.S. population, though the higher prevalence of White 
patients in this sample relative to the general population is consistent with previous studies 
of racial variations in total joint arthroplasty [36]. There is also the potential for inaccuracies 
in ICD-9 and CPT codes available for extraction from the dataset, though limited the 
analysis to those with confirmed RA/OA by requiring at least two ICD-9 codes for the 
respective disease in each patient retained in the analysis to prevent a diagnosis error. The 
modest number of persons with HIV/AIDS, cancer, SLE, and immunodeficiency conditions 
limit the strength of this analysis as least as it pertains to definitive understanding of the link 
between these conditions and infection risk. The test of moderation between RA/OA status 
and infection should be confirmed in a sample that includes more RA patients, and more 
patients who are taking immunosuppressive medications. In particular, given the relatively 
small percentage of patients with RA compared with OA in addition to the low prevalence of 
use for individual immunomodulating and immunosuppressive medications, it was not 
possible to investigate the relationship between infection risk and diagnosis of OA/RA for 
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each of these medications. This last limitation is mitigated by the observation that the risk of 
infection among RA patients relative to those with OA was elevated only among those not 
taking immunosuppressive medications, but there was no risk differential among those who 
were.
5. Conclusion
In conclusion, this study uses a robust sample to validate previously-identified risk factors 
(i.e., male gender, obesity) and further clarify risk factors with conflicting or very little prior 
research (i.e., gout, prednisone, immunosuppressive medication use). These findings 
contribute to our understanding of treatment- versus disease-related infection risks following 
total joint arthroplasty.
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DMARDs disease modifying anti-rheumatic drugs
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CPT current procedural terminology
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HIV/AIDs human immunodeficiency virus infection and acquired immune deficiency 
syndrome
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Figure 1. 
Derivation of Sample.
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Figure 2. 
Comparisons of medication usage rates between cases and controls.
Note: Above each bar is listed the percent of patients taking that drug who have RA, whether 
in the case or control group; this should be contrasted to 8%, the percent of patients with RA 
in the full sample of cases and controls. For example, all patients taking Adalimumab who 
did not get infections had RA, and 80% of those in the case group who were taking this drug 
had RA.
Salt et al. Page 13
Semin Arthritis Rheum. Author manuscript; available in PMC 2018 February 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 3. 
Comparison of use of TNFα inhibitors and traditional DMARDs between cases and 
controls.
*TNFα inhibitors including Adalimumab, Certolizumab, Etanercept, Infliximab, and 
Golimumab
±Traditional DMARDS including Azathioprine, Hydroxychloroquine, Leflunomide, and 
Methotrexate
Note: Above each bar is listed the percent of patients taking that class of drug who have RA, 
whether in the case or control group; this should be contrasted to 8%, the percent of patients 
with RA in the full sample of cases and controls. For example, 93% of patients taking a 
TNFα inhibitor who did not get infections had RA, and 69% of those in the case group who 
were taking this class of drug had RA.
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Table 1
Descriptive summary of study variables and comparisons by infection status
Total sample (N = 2,212) Case (n = 1,106) Control (n = 1,106) p
Gender .002
 Male 1,081 (48.9%) 576 (52.1%) 505 (45.7%)
 Female 1,131 (51.1%) 530 (47.9%) 601 (54.3%)
Race .50
 White 1,838 (83.1%) 913 (82.5%) 925 (83.6%)
 Other 374 (16.9%) 193 (17.5%) 181 (16.4%)
Surgery location .58
 Knee 1,361 (61.5%) 692 (62.6%) 669 (60.5%)
 Hip 789 (35.7%) 385 (34.8%) 404 (36.5%)
 Shoulder 62 (2.8%) 29 (2.6%) 33 (3.0%)
Follow-up (days) 555 (301 – 814.5) 577 (335 - 832) 525.5 (260 -786) <.001
Cancer .13
 Yes 55 (2.5%) 33 (3.0%) 22 (2.0%)
 No 2,157 (97.5%) 1,073 (97.0%) 1,084 (98.0%)
Lupus (SLE) .007
 Yes 56 (2.5%) 38 (3.4%) 18 (1.6%)
 No 2,156 (97.5%) 1,068 (96.6%) 1,088 (98.4%)
Immunodeficiency condition .087
 Yes 22 (1.0%) 15 (1.4%) 7 (0.6%)
 No 2,190 (99.0%) 1,091 (98.6%) 1,099 (99.4%)
HIV/AIDS .74
 Yes 9 (0.4%) 5 (0.5%) 4 (0.4%)
 No 2,203 (99.6%) 1,101 (99.5%) 1,102 (99.6%)
Diabetes <.001
 Yes 651 (29.4%) 377 (34.1%) 274 (24.8%)
 No 1,561 (70.6%) 729 (65.9%) 832 (75.2%)
Obesity <.001
 Yes 675 (30.5%) 396 (35.8%) 279 (25.2%)
 No 1,537 (69.5%) 710 (64.2%) 827 (74.8%)
Gout <.001
 Yes 142 (6.4%) 99 (8.9%) 43 (3.9%)
 No 2,070 (93.6%) 1,007 (91.1%) 1,063 (96.1%)
Perioperative prednisone use <.001
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Total sample (N = 2,212) Case (n = 1,106) Control (n = 1,106) p
 Yes 502 (22.7%) 306 (27.7%) 196 (17.7%)
 No 1,710 (77.3%) 800 (72.3%) 910 (82.3%)
Perioperative immunosuppressive medication use <.001
 Yes 299 (13.5%) 184 (16.6%) 115 (10.4%)
 No 1,913 (86.5%) 922 (83.4%) 991 (89.6%)
Diagnosis .005
 Rheumatoid arthritis 169 (7.6%) 102 (9.2%) 67 (6.1%)
 Osteoarthritis 2,043 (92.4%) 1,004 (90.8%) 1,039 (93.9%)
Note: all statistics are reported as n (%), except days of follow-up; this is reported as median (interquartile range)
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Table 2
Multiple logistic regression modeling the likelihood of developing a post-operative 
infection following total joint replacement surgery (N = 2,212)
Estimated Odds Ratio (OR) 95% Confidence Interval for OR p
Gender
 Male vs. female 1.42 1.19 – 1.70 <.001
Race
 White vs. other 0.93 0.74 – 1.17 .53
Replacement surgery location
 Hip vs. knee 1.01 0.84 – 1.21 .93
 Shoulder vs. knee 0.78 0.46 – 1.33 .36
 Follow-up (days) a 1.04 1.01 – 1.07 .004
Cancer
 Yes vs. no 1.34 0.76 – 2.36 .31
Lupus (SLE)
 Yes vs. no 1.65 0.90 – 3.04 .11
Immunodeficiency condition
 Yes vs. no 1.78 0.69 – 4.57 .23
HIV/AIDS
 Yes vs. no 1.24 0.32 – 4.82 .76
Diabetes
 Yes vs. no 1.38 1.14 – 1.68 .001
Obesity
 Yes vs. no 1.66 1.37 – 2.02 <.001
Gout
 Yes vs. no 1.95 1.30 – 1.97 .001
Perioperative prednisone use
 Yes vs. no 1.59 1.28 – 1.97 <.001
Perioperative immunosuppressive medication use
 Yes vs. no 1.12 0.84 – 1.50 .44
Diagnosis
 RA vs. OA 1.47 1.04 – 2.08 .031
a
Estimates correspond to a 100 day increase days of follow-up
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